Androgen receptor-targeted treatments for breast cancer are in development and have shown promising preliminary results.25–28 One direction in preclinical and clinical research is the use of AR antagonists in triple-negative breast cancer25,26,28–30 but up to now, no reliable biomarker has been identified to predict response. This evidence concerns the gene AR and breast carcinoma.